Wallbach, Manuel

[["dc.bibliographiccitation.firstpage","3051"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Journal of Clinical Medicine"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Lipphardt, Mark"],["dc.contributor.author","Dihazi, Hassan"],["dc.contributor.author","Maas, Jens-Holger"],["dc.contributor.author","Schäfer, Ann-Kathrin"],["dc.contributor.author","Amlaz, Saskia I."],["dc.contributor.author","Ratliff, Brian B."],["dc.contributor.author","Koziolek, Michael J."],["dc.contributor.author","Wallbach, Manuel"],["dc.date.accessioned","2021-04-14T08:32:33Z"],["dc.date.available","2021-04-14T08:32:33Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.3390/jcm9093051"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17590"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/83944"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.notes.intern","Merged from goescholar"],["dc.publisher","MDPI"],["dc.relation.eissn","2077-0383"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Syndecan-4 as a Marker of Endothelial Dysfunction in Patients with Resistant Hypertension"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","199"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","BMC Nephrology"],["dc.bibliographiccitation.volume","20"],["dc.contributor.author","Delistefani, Fani"],["dc.contributor.author","Wallbach, Manuel"],["dc.contributor.author","Müller, Gerhard A"],["dc.contributor.author","Koziolek, Michael J"],["dc.contributor.author","Grupp, Clemens"],["dc.date.accessioned","2019-07-09T11:51:45Z"],["dc.date.available","2019-07-09T11:51:45Z"],["dc.date.issued","2019"],["dc.description.abstract","Abstract Background Due to rising vascular comorbidities of patients undergoing dialysis, the prevalence of permanent hemodialysis catheters as hemodialysis access is increasing. However, infection is a major complication of these catheters. Therefore, identification of potential predicting risk factors leading to early infection related complications is valuable, in particular the significance the CRP (C-reactive protein)-value is of interest. Methods In this retrospective study 151 permanent hemodialysis catheters implanted in 130 patients were examined. The following data were collected at the time of catheter implantation: CRP-value, history of catheter-related infection, microbiological status, immunosuppression and diabetes mellitus. The primary outcomes were recorded over the 3 months following the implantation: catheter-related infection, days of hospital stay and death. Catheter removal or revision, rehospitalization and use of antibiotics were identified as secondary outcomes. Results We identified a total of 27 (17.9%) infections (systemic infection: 2.26 episodes/ 1000 catheter days, local infection: 0.6 episodes/ 1000 catheter days). The development of an infection was independent of the CRP-value (p = 0.66) as well as the presence of diabetes mellitus (p = 0.64) or immunosuppression (p = 0.71). Univariate analysis revealed that infection was more frequent in patients with MRSA-carriage (p < 0.001), in case of previous catheter-related infection (p < 0.05) and of bacteremia or bacteriuria in the period of 3 months before catheter implantation (p < 0.001). Catheter removal or revision (p = 0.002), rehospitalization (p = 0.001) and use of antibiotics (p = 0.02) were also more often observed in patients with MRSA-carriage. Conclusions The CRP-value at the time of implantation of a permanent hemodialysis catheter is not associated with the development of early catheter related infections, but an individual history of catheter-related infection, MRSA-carriage and bacteremia or bacteriuria in the period of 3 months prior to catheter implantation are significant risk factors."],["dc.identifier.doi","10.1186/s12882-019-1392-0"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16186"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/60004"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.publisher","BioMed Central"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Risk factors for catheter-related infections in patients receiving permanent dialysis catheter"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1597"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Journal of Clinical Medicine"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Lipphardt, Mark"],["dc.contributor.author","Wallbach, Manuel"],["dc.contributor.author","Koziolek, Michael J."],["dc.date.accessioned","2021-04-14T08:26:23Z"],["dc.date.available","2021-04-14T08:26:23Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.3390/jcm9051597"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/81923"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.publisher","MDPI"],["dc.relation.eissn","2077-0383"],["dc.rights","https://creativecommons.org/licenses/by/4.0/"],["dc.title","Plasma Exchange or Immunoadsorption in Demyelinating Diseases: A Meta-Analysis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Journal of Clinical Hypertension"],["dc.contributor.author","Schäfer, Ann-Kathrin C."],["dc.contributor.author","Müller, Dieter"],["dc.contributor.author","Born, Ellen"],["dc.contributor.author","Mühlhaus, Maria"],["dc.contributor.author","Lüders, Stephan"],["dc.contributor.author","Wallbach, Manuel"],["dc.contributor.author","Koziolek, Michael J."],["dc.date.accessioned","2022-08-11T12:35:08Z"],["dc.date.available","2022-08-11T12:35:08Z"],["dc.date.issued","2022-07-23"],["dc.description.abstract","Therapy adherence significantly determines the success of antihypertensive therapy, especially in patients with resistant hypertension. Our study investigates the impact of drug adherence on the efficacy of Baroreflex-activation-therapy (BAT). In this retrospective analysis, the authors measured blood pressure (BP) and antihypertensive medication adherence (by gas chromatography-mass spectrometry [GC-MS] urine analysis) before and 6 months after BAT initiation. Adherence was defined as detection of ≥80% intake of prescribed medication at the time of follow-up. Response to BAT was defined as BP drop ≥5 mmHg in systolic 24 h-ambulatory BP (ABP) after 6 months. Overall patients (n = 38) median medication adherence was low, but rose from 60% (IQR 25%-100%) to 75% (IQR 38%-100%; p = .0194). After 6 months of BAT, mean systolic and diastolic office BP (-21 ± 25 mmHg and -9 ± 15 mmHg; p < .0001 and .0004) as well as 24 h-ABP dropped significantly (-9 ± 17 mmHg and -5 ± 12 mmHg; p = .0049 and .0280). After 6 months of BAT, 21 patients (60%) could be classified as responders. There was neither significant difference in mean office systolic (-21 ± 23 mmHg vs. -21 ± 28 mmHg; p = .9581) nor in 24 h-systolic ABP decrease (-11 ± 19 mmHg vs. -7 ± 15 mmHg; p = .4450) comparing adherent and non-adherent patients. Whereas Antihypertensive Therapeutic Index (ATI) was unchanged in non-responders, it significantly decreased in responders (from 50 ± 16 to 46 ± 16; p = .0477). These data are the first to show that BAT-initiation leads to a clear BP reduction independently of patients´ medication adherence. Response to BAT is associated with a significant lowering of ATI, which might contribute to an underestimation of BAT efficacy."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2022"],["dc.identifier.doi","10.1111/jch.14540"],["dc.identifier.pmid","35870124"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/112711"],["dc.language.iso","en"],["dc.relation.eissn","1751-7176"],["dc.relation.issn","1524-6175"],["dc.relation.issn","1751-7176"],["dc.rights","CC BY-NC-ND 4.0"],["dc.title","Impact of medication adherence on the efficacy of Baroreflex activation therapy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","639"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Journal of Clinical Medicine"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Koziolek, Michael"],["dc.contributor.author","Mueller, Gerhard A."],["dc.contributor.author","Dihazi, Gry H."],["dc.contributor.author","Jung, Klaus"],["dc.contributor.author","Altubar, Constanze"],["dc.contributor.author","Wallbach, Manuel"],["dc.contributor.author","Markovic, Ivana"],["dc.contributor.author","Raddatz, Dirk"],["dc.contributor.author","Jahn, Olaf"],["dc.contributor.author","Karaköse, Hülya"],["dc.contributor.author","Lenz, Christof"],["dc.contributor.author","Urlaub, Henning"],["dc.contributor.author","Dihazi, Abdelhi"],["dc.contributor.author","El Meziane, Abdellatif El"],["dc.contributor.author","Dihazi, Hassan"],["dc.date.accessioned","2020-12-10T18:47:13Z"],["dc.date.available","2020-12-10T18:47:13Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.3390/jcm9030639"],["dc.identifier.eissn","2077-0383"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17408"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/78682"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.publisher","MDPI"],["dc.relation.eissn","2077-0383"],["dc.rights","https://creativecommons.org/licenses/by/4.0/"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Urine E-cadherin: A Marker for Early Detection of Kidney Injury in Diabetic Patients"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","5458"],["dc.bibliographiccitation.issue","18"],["dc.bibliographiccitation.journal","Journal of Clinical Medicine"],["dc.bibliographiccitation.volume","11"],["dc.contributor.affiliation","Aydilek, Enver; 1Department of Hematology and Medical Oncology, University Medicine Göttingen, 37075 Göttingen, Germany"],["dc.contributor.affiliation","Wallbach, Manuel; 2Department of Nephrology and Rheumatology, University Medical Center Göttingen, 37075 Göttingen, Germany"],["dc.contributor.affiliation","Koziolek, Michael; 2Department of Nephrology and Rheumatology, University Medical Center Göttingen, 37075 Göttingen, Germany"],["dc.contributor.affiliation","Wulf, Gerald Georg; 1Department of Hematology and Medical Oncology, University Medicine Göttingen, 37075 Göttingen, Germany"],["dc.contributor.affiliation","Brökers, Nils; 1Department of Hematology and Medical Oncology, University Medicine Göttingen, 37075 Göttingen, Germany"],["dc.contributor.author","Aydilek, Enver"],["dc.contributor.author","Wallbach, Manuel"],["dc.contributor.author","Koziolek, Michael"],["dc.contributor.author","Wulf, Gerald Georg"],["dc.contributor.author","Brökers, Nils"],["dc.contributor.editor","Tanaka, Hiroshi"],["dc.date.accessioned","2022-10-04T10:21:11Z"],["dc.date.available","2022-10-04T10:21:11Z"],["dc.date.issued","2022"],["dc.date.updated","2022-11-11T13:13:01Z"],["dc.description.abstract","Background: The determination of renal function is crucial for the clinical management of patients with cancer. The glomerular filtration rate (GFR) serves as a key parameter, estimated by creatinine clearance determination in 24-h collected urine (CrCl) as well as equation-based approaches (eGFR) relying on serum creatinine (eGFR CKD EPIcrea) or serum cystatin C (eGFR cystatin C). Serum creatinine and serum cystatin C levels differentially depend on muscle and tumor mass, respectively. Although muscle and tumor mass may thus represent confounding factors, comparative studies for eGFR estimate approaches in cancer patients are lacking. Methods: The present study retrospectively analyzed GFR estimates based on equations of creatinine (eGFRcr), cystatin C (eGFRcys) and combined creatinine-cystatin C levels (eGFRcr-cys) in a subset of patients. The associations of LDH with cystatin C or LDH with eGFRcr, eGFRcys and GFRcr-cys were explored. Results: The laboratory values of 123 consecutive patients were included. The median age was 59 (24–87) and 47.2% were female. There was a statistically significant difference in the mean of CKD EPIcrea (85.17 ± 21.63 mL/min/1.73 m2), CKD EPIcys (61.16 ± 26.03 mL/min/1.73 m2) and CKD EPIcrea-cys (70.42 ± 23.89 mL/min/1.73 m2) (p < 0.0001). Spearman’s correlation analysis revealed a significant correlation of elevated plasma LDH >1.5 UNV and cystatin C values (r = 0.270, p < 0.01, n = 123). LDH values >1.5 UNV were associated with significantly lower CKD EPIcys (r = 0.184, p < 0.01) or CKD EPIcrea-cys (r = 0.226, p < 0.05) estimates compared to CKD EPIcrea. Conclusions: The inclusion of cystatin C as a biomarker led to a lower eGFR estimates compared to creatinine alone or in a combination of both cystatin C and creatinine. The level of cystatin C correlated with the level of LDH, suggesting that the use of cystatin C-based calculations of GFR in cancer patients with elevated LDH should be used with caution."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2022"],["dc.identifier.doi","10.3390/jcm11185458"],["dc.identifier.pii","jcm11185458"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/114347"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-600"],["dc.publisher","MDPI"],["dc.relation.eissn","2077-0383"],["dc.rights","Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)."],["dc.title","Impact of Elevated LDH on Cystatin C-Based Glomerular Filtration Rate Estimates in Patients with Cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1363"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Journal of Clinical Hypertension"],["dc.bibliographiccitation.lastpage","1371"],["dc.bibliographiccitation.volume","23"],["dc.contributor.author","Schäfer, Ann‐Kathrin"],["dc.contributor.author","Kuczera, Tim"],["dc.contributor.author","Wurm‐Kuczera, Rebecca"],["dc.contributor.author","Müller, Dieter"],["dc.contributor.author","Born, Ellen"],["dc.contributor.author","Lipphardt, Mark"],["dc.contributor.author","Plüss, Marlene"],["dc.contributor.author","Wallbach, Manuel"],["dc.contributor.author","Koziolek, Michael"],["dc.date.accessioned","2021-07-05T14:57:42Z"],["dc.date.available","2021-07-05T14:57:42Z"],["dc.date.issued","2021"],["dc.description.sponsorship","Open-Access-Publikationsfonds 2021"],["dc.identifier.doi","10.1111/jch.14302"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/87713"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-441"],["dc.relation.eissn","1751-7176"],["dc.relation.issn","1524-6175"],["dc.relation.orgunit","Klinik für Nephrologie und Rheumatologie"],["dc.rights","CC BY-NC 4.0"],["dc.title","Eligibility for Baroreflex Activation Therapy and medication adherence in patients with apparently resistant hypertension"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","3999"],["dc.bibliographiccitation.issue","17"],["dc.bibliographiccitation.journal","Journal of Clinical Medicine"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Korsten, Peter"],["dc.contributor.author","Kuczera, Tim"],["dc.contributor.author","Wallbach, Manuel"],["dc.contributor.author","Tampe, Björn"],["dc.contributor.editor","Kusztal, Mariusz"],["dc.contributor.editor","Turkmen, Kultigin"],["dc.date.accessioned","2021-10-01T09:58:27Z"],["dc.date.available","2021-10-01T09:58:27Z"],["dc.date.issued","2021"],["dc.description.abstract","Background: Chronic kidney disease (CKD) is a common medical problem in patients worldwide, with an increasing prevalence of patients with end-stage kidney disease (ESKD) requiring renal replacement therapy (RRT). In patients requiring RRT for more than two weeks or those who develop ESKD, tunneled hemodialysis catheter (HDC) insertion is preferred, based on a lower risk for infectious complications. While the efficacy of ultrasound (US)-guided tip positioning in antegrade-tunneled HDCs has previously been shown, its application for the insertion of retrograde-tunneled HDCs has not been described yet. This is especially important, since the retrograde-tunneled technique has several advantages over the antegrade-tunneled HDC insertion technique. Therefore, we here report our first experience of applying the rapid atrial swirl sign (RASS) for US-guided tip positioning of retrograde-tunneled HDCs. Methods: We performed a cross-sectional study to assess the feasibility of applying the RASS for US-guided tip positioning of retrograde-tunneled HDCs. We performed a total number of 24 retrograde-tunneled HDC insertions in 23 patients (requiring placement of a HDC for the temporary or permanent treatment of ESKD) admitted to our Department of Nephrology and Rheumatology at the University Medical Center Göttingen, Germany. Results: The overall success rate of applying the RASS for US-guided tip positioning of retrograde-tunneled HDCs was 24/24 (100%), with proper tip position in the right atrium in 18/23 (78.3%), or cavoatrial junction in 5/23 (21.7%) when RASS was positive and improper position when RASS was negative in 1/1 (100%), confirmed by portable anterior-posterior chest radiography, with only minor post-procedural bleeding in 2/24 (8.3%). In addition, this insertion technique allows optimal HDC flow, without any observed malfunction. Conclusion: This is the first study to investigate the efficacy of the RASS for US-guided tip positioning of retrograde-tunneled HDCs in patients with ESKD. Application of the RASS for US-guided tip positioning is an accurate and safe procedure for the proper placement of retrograde-tunneled HDCs."],["dc.description.abstract","Background: Chronic kidney disease (CKD) is a common medical problem in patients worldwide, with an increasing prevalence of patients with end-stage kidney disease (ESKD) requiring renal replacement therapy (RRT). In patients requiring RRT for more than two weeks or those who develop ESKD, tunneled hemodialysis catheter (HDC) insertion is preferred, based on a lower risk for infectious complications. While the efficacy of ultrasound (US)-guided tip positioning in antegrade-tunneled HDCs has previously been shown, its application for the insertion of retrograde-tunneled HDCs has not been described yet. This is especially important, since the retrograde-tunneled technique has several advantages over the antegrade-tunneled HDC insertion technique. Therefore, we here report our first experience of applying the rapid atrial swirl sign (RASS) for US-guided tip positioning of retrograde-tunneled HDCs. Methods: We performed a cross-sectional study to assess the feasibility of applying the RASS for US-guided tip positioning of retrograde-tunneled HDCs. We performed a total number of 24 retrograde-tunneled HDC insertions in 23 patients (requiring placement of a HDC for the temporary or permanent treatment of ESKD) admitted to our Department of Nephrology and Rheumatology at the University Medical Center Göttingen, Germany. Results: The overall success rate of applying the RASS for US-guided tip positioning of retrograde-tunneled HDCs was 24/24 (100%), with proper tip position in the right atrium in 18/23 (78.3%), or cavoatrial junction in 5/23 (21.7%) when RASS was positive and improper position when RASS was negative in 1/1 (100%), confirmed by portable anterior-posterior chest radiography, with only minor post-procedural bleeding in 2/24 (8.3%). In addition, this insertion technique allows optimal HDC flow, without any observed malfunction. Conclusion: This is the first study to investigate the efficacy of the RASS for US-guided tip positioning of retrograde-tunneled HDCs in patients with ESKD. Application of the RASS for US-guided tip positioning is an accurate and safe procedure for the proper placement of retrograde-tunneled HDCs."],["dc.identifier.doi","10.3390/jcm10173999"],["dc.identifier.pii","jcm10173999"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/90065"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-469"],["dc.publisher","MDPI"],["dc.relation.eissn","2077-0383"],["dc.rights","Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)."],["dc.title","The Rapid Atrial Swirl Sign for Ultrasound-Guided Tip Positioning of Retrograde-Tunneled Hemodialysis Catheters: A Cross-Sectional Study from a Single Center"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","202"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Blood Purification"],["dc.bibliographiccitation.lastpage","213"],["dc.bibliographiccitation.volume","42"],["dc.contributor.author","Dihazi, Hassan"],["dc.contributor.author","Koziolek, Michael Johann"],["dc.contributor.author","Datta, Rabi R."],["dc.contributor.author","Wallbach, Manuel"],["dc.contributor.author","Jung, Klaus"],["dc.contributor.author","Heise, Daniel"],["dc.contributor.author","Dihazi, Gry Helene"],["dc.contributor.author","Markovic, Ivana"],["dc.contributor.author","Asif, Abdul R."],["dc.contributor.author","Müller, Gerhard A."],["dc.date.accessioned","2018-11-07T10:20:00Z"],["dc.date.available","2018-11-07T10:20:00Z"],["dc.date.issued","2016"],["dc.description.abstract","Background/Aims: Early initiation of renal replacement therapy (RRT) is recommended in order to improve the clinical outcome of patients who develop an acute kidney injury (AKI). However, markers that guide an early RRT initiation do not really exist currently. Methods: Urine and serum samples were prospectively collected from 120 AKI patients. Depending on the necessity of initiating RRT, patients were divided into 2 different groups: dialysis (n = 52) and non-dialysis (n = 68). Results: Comparative urinary proteomic analyses identified 4 different proteins (fatty acid binding proteins 1 and 3 (FABP1 and FABP3), beta-2-microglobulin (B2M), cystatin-M (CST6)) that discriminate AKI patients with high risk for RRT. Western blot analysis confirmed the proteomics data for FABP1 and FABP3 but not for B2M and CST6. Validation analysis confirmed that the FABP1 and FABP3 fulfilled the requirement of functioning as markers for AKI patients with risk to dialysis (p < 0.001). Conclusion: The release of high amounts of FABP1 and FABP3 in urine of AKI patients could serve as a diagnostic/prognosis marker for RRT initiation in these patients. (C) 2016 S. Karger AG, Basel"],["dc.identifier.doi","10.1159/000447115"],["dc.identifier.isi","000383965100004"],["dc.identifier.pmid","27355328"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41790"],["dc.language.iso","en"],["dc.notes.intern","DeepGreen Import"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","S. Karger AG"],["dc.relation.eissn","1421-9735"],["dc.relation.issn","1421-9735"],["dc.relation.issn","0253-5068"],["dc.rights","https://www.karger.com/Services/SiteLicenses"],["dc.title","FABP1 and FABP3 Have High Predictive Values for Renal Replacement Therapy in Patients with Acute Kidney Injury"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","371"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","American Journal of Nephrology"],["dc.bibliographiccitation.lastpage","380"],["dc.bibliographiccitation.volume","40"],["dc.contributor.author","Wallbach, Manuel"],["dc.contributor.author","Lehnig, Luca-Yves"],["dc.contributor.author","Schroer, Charlotte"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Mueller, Gerhard-Anton"],["dc.contributor.author","Wachter, Rolf"],["dc.contributor.author","Koziolek, Michael J."],["dc.date.accessioned","2017-09-07T11:46:54Z"],["dc.date.available","2017-09-07T11:46:54Z"],["dc.date.issued","2014"],["dc.description.abstract","Background/Aims: Resistant hypertension and chronic kidney disease (CKD) are interlinked via sympathetic overdrive. Baroreflex activation therapy (BAT) has been shown to chronically reduce blood pressure (BP) in patients with resistant hypertension. The effect of BAT on renal function in CKD patients with resistant hypertension has not been reported. The aim of this study was to investigate the effect of sympathetic inhibition on renal function in CKD patients. Methods: 23 CKD patients with resistant hypertension were prospectively treated with BAT. Analyses were performed before and 6 months after the start of BAT. The renal function was analyzed by creatinine, cystatin C, glomerular filtration rate (GFR), renin, aldosterone, fractioned and 24-hour sodium excretion and analyses of urine marker proteins. The purpose of the control group was to investigate the influence of treating patients in a center for hypertension and regression to the mean on investigated variables. Results:The office mean BP decreased from 116.9 +/- 20.9 mm Hg to 104.2 +/- 22.2 mm Hg (p < 0.01), while the number of prescribed antihypertensive classes decreased from 6.6 +/- 1.6 to 6.1 +/- 1.7 (p = 0.02). Proteinuria and albuminuria decreased from a median of 283.9 and 47.7 to 136.5 (p = 0.01) and 45.0 mg/g creatinine (p = 0.01) with pronounced effects in higher CKD stage III + IV compared to I + II (p < 0.01). CKD-EPI cystatin C equation improved from 53.6 +/- 22.7 to 60.4 +/- 26.1 ml/min (p = 0.02). While creatinine and GFR were impaired after a period of 6 months, no changes of proteinuria, albuminuria, or BP were obtained in control patients. Conclusion: The data of this prospective trial demonstrate potential nephroprotective effects of BAT in therapy-resistant hypertension in CKD patients by a reduction of BP, proteinuria and moreover, a stabilization of estimated GFR. (C) 2014 S. Karger AG, Basel"],["dc.identifier.doi","10.1159/000368723"],["dc.identifier.gro","3142203"],["dc.identifier.isi","000345194900009"],["dc.identifier.pmid","25358549"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/5677"],["dc.language.iso","en"],["dc.notes.intern","WoS Import 2017-03-10 / Funder: CVRx"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","S. Karger AG"],["dc.relation.eissn","1421-9670"],["dc.relation.issn","0250-8095"],["dc.rights","https://www.karger.com/Services/SiteLicenses"],["dc.title","Impact of Baroreflex Activation Therapy on Renal Function - A Pilot Study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dspace.entity.type","Publication"]]